ACHP
ALLIANCE
OF COMMUNITY HEALTH PLANS

March 16, 2026

The Honorable August Pfluger
United States House of Representatives
Washington, DC 20515

The Honorable Mike Lee
United States Senate
Washington, DC 20515

The Honorable Greg Landsman
United States House of Representatives
Washington, DC 20515

The Honorable Ben Ray Luján
United States Senate
Washington, DC 20515

Dear Representative Pfluger, Representative Landsman, Senator Lee and Senator Luján:

On behalf of the Alliance of Community Health Plans (ACHP), I write to express strong support for the Biosimilar Red Tape Elimination Act (H.R. 5526/S. 1954). This important legislation would remove outdated regulatory barriers that delay patient access to safe, effective and essential biosimilar medications.

The Alliance of Community Health Plans (ACHP) is the only national organization promoting the unique payer-provider aligned model in health care. ACHP member companies collaborate with their provider partners to deliver higher-quality coverage and care to tens of millions of Americans across 40 states and D.C.

Biosimilars offer tremendous potential to reduce healthcare costs while expanding treatment options for patients with serious life-altering conditions. Typically priced 15% to 35% lower than their brand-name reference biologics, these therapies have generated more than $56 billion in savings since entering the U.S. market in 2015. Greater adoption could generate up to $121 billion in additional savings by 2033. Despite these savings, biosimilar uptake has been slower than expected due in-part to outdated statutory requirements. Current law requires biosimilar manufacturers to complete additional studies to receive an "interchangeability" designation, even after the Food and Drug Administration (FDA) has already determined that the biosimilar is safe and effective. The FDA has consistently affirmed that there is no scientific difference between biosimilars and interchangeable biologics. FDA Commissioner Marty Makary has announced the Agency's intent to finalize guidance eliminating the requirement for switching studies and support for removal of the interchangeability designation. These duplicative requirements increase costs and delay the availability of lower-cost alternatives for patients.

The Biosimilar Red Tape Elimination Act is consistent with FDA's science-based recommendation and represents an important step toward building confidence and streamlining patient access to biosimilar medicines. By removing the separate interchangeability designation and deeming FDA-approved biosimilars as interchangeable with their reference biologics, this commonsense reform would reduce unnecessary costs and increase competition in the pharmaceutical market.

ACHP member companies are already promoting biosimilar adoption by educating clinicians and patients about new treatment options and by designing formularies that encourage the use of high-value therapies. When biosimilars are used more broadly, the health care system benefits from increased competition and savings while patients continue to receive high quality care.

If you would like to discuss these recommendations further, please contact Madeline O'Brien, Associate Director, Legislative Affairs at (mobrien@achp.org). ACHP appreciates your leadership in introducing this legislation and looks forward to continuing to work with you to achieve its enactment as soon as possible.

Sincerely,

Ceci Connolly

Ceci Connolly
President and Chief Executive Officer
Alliance of Community Health Plans